Improving life for cancer patients through transformative drugs




New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Read more

Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Read more

Resolutions at the Annual General Meeting in Medivir on 9 May 2019

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.